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work is needed to determine whether interventions aimed
at these patients will result in improved quality of life.
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OBJECTIVE: It has been estimated that 92% of geriatric
psychiatric patients have at least 1 comorbid physical dis-
order. The baby boomers will be turning 65 by 2011 and
over 130 million people will be over 45 by 2050. The se-
vere and persistently mentally population have not been
extensively studied concerning comorbidities and physi-
cal and behavioral risk factors of cardiovascular disease.
We propose to determine the cost of treatment and prev-
alence of these comorbidities and risk factors in this pop-
ulation. METHODS: We conducted a chart review of all
adult inpatients (N  179) of a state psychiatric hospital
during July and August 2000. All subjects had a medical
history, physical exam, screening blood tests, ECG and
medical service utilization data collected. The cost of
treatment and prevalence of cardiovascular disease in our
population was compared to a control group of Medicaid
recipients matched for age and sex. RESULTS: Subject
Characteristics: 47  16 years; 113 male; 29% African
American, 10% Hispanic. Cardiovascular Disease Co-
morbidities: 40% ECG abnormalities, 15% Hyperten-
sion, 10% Diabetes, 7% Thyroid Dysfunction, 6% CAD.
Physical and Behavioral Risk Factors: 69% overweight
(BMI  25), 38% obese (BMI  30); 18% hyperlipi-
demia, 67% nicotine & 49% alcohol abuse, 35% chemi-
cally addicted. Cost of Treatment: Total cost: $2539
($2257–$2821), Cost of cardiovascular disease comor-
bidities: $3889 ($2105–$5673). CONCLUSION: 49%
had cardiovascular disease comorbidities. 62% had mul-
tiple behavioral and physical risk factors for developing
cardiovascular disease in their life time. The sample size
limits our ability to make population inferences yet an as-
sociation between severe and persistently mentally ill pa-
tients and a increased risk for cardiovascular disease ex-
ists in our group (T  8.101, df  356, P  .00001).
This association is also evident in the greater cost of
treatment $1985 ($1518–$2452) of the severe and persis-
tently mentally ill compared to the control group (T 
4.78, df  108, P  .00001).
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OBJECTIVE: Methods to develop resource costs from
administrative data remain underdeveloped. Our objec-
tive was to improve current methods of estimating daily
hospitalization cost by determining the pattern of re-
source utilization for patients hospitalized with cardio-
vascular-related diagnoses. METHODS: Using a propri-
etary cost-accounting system, we assessed the proportion
of total hospital costs for each hospital day for patients
within 10 DRGs. From these proportions, a series of
equations were developed to calculate cost for each day
of hospitalization. The dataset for this analysis included
records for 2,698 patients for FY 2000. RESULTS:
27.39% of costs occurred on Day 1 for medical DRG
127 (Heart Failure, ALOS  5). For each of the remain-
ing four days the proportion of cost was 18.15%. For
surgical DRG 112 (PTCA, ALOS  3), 65.56% of costs
occurred on Day 1 and 17% occurred on each of the re-
maining two days. The average proportion of costs for
the first day of hospitalization and for each day thereafter
for the remaining medical and surgical DRGs were 30%
and 17%, and 62% and 19%, respectively. To illustrate,
the average cost per day of a DRG 112 hospitalization
was $4,333, totaling $13,000. By using the developed
equations, the cost for the first day of hospitalization was
calculated to be $8,500. The cost for each remaining day
was $2,238.60. In this example, use of an average cost
per day overestimates the marginal cost of the last day by
approximately $2,000. CONCLUSION: Average cost
per day grossly overestimates the cost savings of reduced
length of stay, especially for surgical diagnoses. The de-
veloped methodology will more accurately reflect any
cost savings from a reduced length of stay by accounting
for the greater intensity of care during the first day of a
hospital admission.
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Peripheral artery disease manifests as intermittent claudi-
cation in over 4 million people in the US. In people older
than 60 years, intermittent claudication occurs in 5% of
men and 3% of women. OBJECTIVES: The purpose of
this study was to develop a cost-utility model to compare
cilostazol, pentoxifylline, and placebo based on pub-
lished randomized control trial data. METHODS: In the
trial, 698 patients received either cilostazol 100 mg twice
a day, pentoxifylline 400 mg 3 times a day, or placebo.
Quality of life was measured with the SF-36. Survival
was projected to be similar between the three groups
from this study of 24 weeks duration and SF-36 was con-
verted to a single utility score using the regression for-
mula published by Bosch. RESULTS: On SF-36, cilosta-
zol was significantly better on the physical components
over baseline. Pentoxifylline and placebo were not signif-
icantly different on either the physical or mental compo-
